Trial Profile
A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2019
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors IMPAX Laboratories
- 04 Dec 2018 Results assessing efficacy of single dose of IPX203 in advanced Parkinson's Disease, published in the Clinical Neuropharmacology.
- 08 Jun 2017 Primary endpoint (Off time per the Assessment of Subjects Motor State) has been met as per the results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders